European News

The CHMP has recommended authorising two vaccines adapted to provide broader protection against COVID-19. Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are for use in people aged 12 years and above who have received at least primary vaccination against COVID-19.

These vaccines are adapted to better fight the circulating variants of SARS-CoV-2. Adapted vaccines can broaden protection against different variants, and are therefore expected to help maintain optimal protection against COVID-19, as the virus continues to evolve.

The ECDC and EMA have issued a joint statement, stating that: “Exposing the immune system to contemporary versions of the virus so that it learns and recognises subsequent variants is key for building up a broader immune response.”

Destiny Pharma has received positive feedback from the EMA regarding the proposed Phase III development programme of its new antibiotic treatment.

The EMA has declared that a single, final-stage study of NTCD-M3, the group’s lead clinical candidate for the prevention of the recurrence of infections caused by toxic strains of the gut bacteria, would be sufficient for it to file a marketing authorisation application.

The group added that the EMA has also endorsed a new capsule formulation of the drug, currently in development with an aim to treat the recurrence of Clostridioides difficile (CDI).